Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Non-inferiority trials are unethical because they disregard patients' interests.

Garattini S, Bertele' V.

Lancet. 2007 Dec 1;370(9602):1875-7. Epub 2007 Oct 23. No abstract available.

PMID:
17959239
2.

Informed consent on trial.

Cressey D.

Nature. 2012 Jan 30;482(7383):16. doi: 10.1038/482016a. No abstract available.

PMID:
22297946
3.

The ethics of non-inferiority trials.

Soliman EZ.

Lancet. 2008 Mar 15;371(9616):895; author reply 896-7. doi: 10.1016/S0140-6736(08)60406-7. No abstract available.

PMID:
18342675
4.

Is it sound public policy to let the terminally ill access experimental medical innovations?

Caplan A.

Am J Bioeth. 2007 Jun;7(6):1-3. No abstract available.

PMID:
17558976
5.

Comments on 'Applying justice in clinical trials for diverse population' by J Tilburt et al.

Kahn J.

Clin Trials. 2007;4(3):270; discussion 271. No abstract available.

PMID:
17715254
6.
7.

The ethics of non-inferiority trials.

Chuang-Stein C, Beltangady M, Dunne M, Morrison B.

Lancet. 2008 Mar 15;371(9616):895-6; author reply 896-7. doi: 10.1016/S0140-6736(08)60407-9. No abstract available.

PMID:
18342677
8.
9.

The ethics of clinical trials for cancer therapy.

Howie LJ, Peppercorn JM.

N C Med J. 2014 Jul-Aug;75(4):270-3.

10.

Minimal risk remains an open question.

Binik A, Weijer C, Sheehan M.

Am J Bioeth. 2011 Jun;11(6):25-7. doi: 10.1080/15265161.2011.568579. No abstract available.

PMID:
21678212
11.

The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.

Markman M.

Cleve Clin J Med. 2003 Dec;70(12):1008-9, 1013-4, 1016. Review. No abstract available.

PMID:
14686681
12.

Incentivizing recruitment and retention to address enrollment challenges in clinical research.

Dickert NW, Halpern SD, Butler J.

Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):367-70. doi: 10.1161/CIRCOUTCOMES.113.000176. Epub 2013 May 7. No abstract available.

13.
14.

The concept of minimal risk: the need for better guidance on the ethics review process.

Wada K.

Am J Bioeth. 2011 Jun;11(6):27-9. doi: 10.1080/15265161.2011.568584. No abstract available.

PMID:
21678213
15.

(Un)risky business: adolescents and HIV prevention trials.

Philpott S.

Am J Bioeth. 2011 Jun;11(6):17-9. doi: 10.1080/15265161.2011.568585. No abstract available.

PMID:
21678207
16.

Clinical trials and methodological problems in prion diseases.

Puopolo M, Pocchiari M, Petrini C.

Lancet Neurol. 2009 Sep;8(9):782; author reply 782-3. doi: 10.1016/S1474-4422(09)70214-5. No abstract available.

PMID:
19679270
17.

Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.

Slack CM.

Am J Bioeth. 2011 Jun;11(6):21-2. doi: 10.1080/15265161.2011.566671. No abstract available.

PMID:
21678209
18.

Uniqueness, exploitation, and relative risk standards in adolescent research.

Malek J.

Am J Bioeth. 2011 Jun;11(6):23-5. doi: 10.1080/15265161.2011.568587. No abstract available.

PMID:
21678211
19.

Clinical trials in China: protection of subjects' rights and interests.

Yuan L.

J Clin Ethics. 2004 Spring;15(1):30-4. No abstract available.

PMID:
15202354
20.

Industry-sponsored clinical trials: the problem of conflicts of interest.

Jia S, Brown D, Wall A, Kodner I, Keune JD.

Bull Am Coll Surg. 2013 May;98(5):32-5. No abstract available.

PMID:
23841318

Supplemental Content

Support Center